OAG
NBIX icon

Oakmont Advisory Group’s Neurocrine Biosciences NBIX Stock Holding History

Oakmont Advisory Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$445K Sell
2,639
-188
-7% -$27.9K 0.37% 60
2026
Q1 		$372K Buy
2,827
+477
+20% +$63.3K 0.38% 71
2025
Q4 		$333K Buy
+2,350
New +$340K 0.36% 82

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Oakmont Advisory Group's NBIX Position: Q2 2026 in Review

Oakmont Advisory Group reduced its Neurocrine Biosciences (NBIX) stake by 6.7% in Q2 2026, selling an estimated $27.9K and leaving 2,639 shares worth $445K. The position accounts for 0.37% of the portfolio, ranked #60.

Oakmont Advisory Group first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 770 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Oakmont Advisory Group held 2,639 shares of Neurocrine Biosciences worth $445K as of Q2 2026.
  • Oakmont Advisory Group sold 188 Neurocrine Biosciences shares in Q2 2026, an estimated $27.9K.
  • Neurocrine Biosciences made up 0.37% of Oakmont Advisory Group's portfolio in Q2 2026, its #60 holding.
  • Oakmont Advisory Group first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Oakmont Advisory Group's 13F filing for Q2 2026, filed 3 Aug 2026.